We could not find any results for:
Make sure your spelling is correct or try broadening your search.
VANCOUVER, British Columbia, Feb. 10, 2021 -- InvestorsHub NewsWire -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or...
VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19 VANCOUVER, British Columbia, June 04, 2020...
Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory Board VANCOUVER, British Columbia, Canada...
Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use VANCOUVER, British Columbia, Canada -- March 13, 2020...
Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus VANCOUVER, British Columbia, Canada -- March 6, 2020 -- InvestorsHub NewsWire -- Algernon...
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD...
Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by...
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments...
#outlook a {padding:0;} body {width:100%; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; margin:0; padding:0;} .ReadMsgBody {width:100%;} .ExternalClass...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.005 | -7.14285714286 | 0.07 | 0.075 | 0.065 | 21241 | 0.072969 | CS |
4 | -0.015 | -18.75 | 0.08 | 0.085 | 0.06 | 42124 | 0.07227127 | CS |
12 | -0.025 | -27.7777777778 | 0.09 | 0.1 | 0.06 | 29969 | 0.07605946 | CS |
26 | -0.055 | -45.8333333333 | 0.12 | 0.14 | 0.06 | 26201 | 0.09462857 | CS |
52 | -0.005 | -7.14285714286 | 0.07 | 0.165 | 0.06 | 30066 | 0.09800924 | CS |
156 | -1.185 | -94.8 | 1.25 | 2.975 | 0.05 | 17803 | 0.24637448 | CS |
260 | 0.0525 | 420 | 0.0125 | 2.975 | 0.01125 | 332694 | 0.07729255 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions